"Oncolytic Viruses" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY.
| Descriptor ID |
D050504
|
| MeSH Number(s) |
B04.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Viruses".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Viruses".
This graph shows the total number of publications written about "Oncolytic Viruses" by people in this website by year, and whether "Oncolytic Viruses" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 3 | 0 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 4 | 0 | 4 |
| 2022 | 3 | 0 | 3 |
| 2023 | 4 | 0 | 4 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 1 | 2 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Viruses" by people in Profiles.
-
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment. Nat Cancer. 2026 May; 7(5):723-739.
-
Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. J Neurooncol. 2026 Feb 25; 177(1).
-
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 07; 643(8070):219-229.
-
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity. Nat Commun. 2025 Apr 24; 16(1):3874.
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 12 09; 12(12).
-
Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent. Mol Cancer Ther. 2024 Sep 04; 23(9):1273-1281.
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 04; 25(4):488-500.
-
Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023 11; 623(7985):157-166.
-
Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. J Transl Med. 2023 07 06; 21(1):444.
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.